Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr 1;137(13):1832-1835.
doi: 10.1182/blood.2020006245.

Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy

Jay Y Spiegel  1 , Saurabh Dahiya  2 , Michael D Jain  3 , John Tamaresis  1 , Loretta J Nastoupil  4 , Miriam T Jacobs  5 , Armin Ghobadi  5 , Yi Lin  6 , Matthew Lunning  7 , Lazaros Lekakis  8 , Patrick Reagan  9 , Olalekan Oluwole  10 , Joseph McGuirk  11 , Abhinav Deol  12 , Andre Goy  13 , Khoan Vu  14 , Charalambos Andreadis  14 , Javier Munoz  15 , N Nora Bennani  6 , Julie M Vose  7 , Kathleen A Dorritie  16 , Sattva S Neelapu  4 , Frederick L Locke  3 , Aaron P Rapoport  2 , Brian T Hill  17 , David B Miklos  1
Affiliations

Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy

Jay Y Spiegel et al. Blood. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Factors affecting survival after axi-cel progression. (A) Unstratified Kaplan-Meier analysis of OS after axi-cel progression. (B-D) OS stratified according to cytokine release syndrome (CRS), bridging therapy and response to axi-cel. Gr, grade; SD, stable disease.
See this image and copyright information in PMC

References

    1. Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019;20(1):31-42. - PMC - PubMed
    1. Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531-2544. - PMC - PubMed
    1. Chow VA, Gopal AK, Maloney DG, et al. Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy. Am J Hematol. 2019;94(8):E209-E213. - PMC - PubMed
    1. Byrne M, Oluwole OO, Savani B, Majhail NS, Hill BT, Locke FL. Understanding and managing large B cell lymphoma relapses after chimeric antigen receptor T cell therapy. Biol Blood Marrow Transplant. 2019;25(11):e344-e351. - PMC - PubMed
    1. Pasquini MC, Locke FL, Herrera AF, et al. Post-marketing use outcomes of an anti-CD19 chimeric antigen receptor (CAR) T cell therapy, axicabtagene ciloleucel (axi-Cel), for the treatment of large B cell lymphoma (LBCL) in the United States (US) [abstract]. Blood. 2019;134(suppl 1). Abstract 764.

Publication types